Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
09:10am, Thursday, 14'th Nov 2024
Bluebird Bio (BLUE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.66 per share a year ago.
After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)
10:36am, Friday, 08'th Nov 2024
The heavy selling pressure might have exhausted for Bluebird (BLUE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio presenting data from gene therapy programs in Sickle Cell Disease and Beta-Thalassemia at the 66th ASH Annual Meeting and Exposition.
Bluebird Bio (BLUE) Stock Dips Amid Market Volatility
03:53pm, Tuesday, 08'th Oct 2024
Bluebird Bio (BLUE, Financial) experienced a significant drop in its stock price, declining by 5.67%. The shares are currently trading at $0.491, with a trading volume of 3.72 million shares, a turnov
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Oct 2024
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement awards of 242
Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements
04:11pm, Wednesday, 02'nd Oct 2024
Bluebird Bio (BLUE, Financial) stock experienced a notable surge of 5.04% to $0.494 per share. The trading volume reached 6.47552 million shares, resulting in a turnover rate of 3.34% and a volatility
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
04:30pm, Friday, 27'th Sep 2024
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”
Bluebird bio to cut 25% of workforce as part of restructuring
07:08am, Tuesday, 24'th Sep 2024
Gene therapy maker bluebird bio said on Tuesday it would cut 25% of its workforce as part of a restructuring program for cost reduction.
SOMERVILLE, Mass.--(BUSINESS WIRE)--Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to o
2 Penny Stocks To Buy With Just $250
05:02pm, Monday, 16'th Sep 2024
There's a trade that's generally accepted anytime someone makes an investment.
My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys
08:10am, Wednesday, 28'th Aug 2024
Investment activity in July focused on Business Development Companies, with $2,000 added to the market. Adjusted dividend income in July of $709, up 19% Y/Y and down 4% sequentially. Main picks includ
bluebird bio, Inc. (BLUE) Q2 2024 Earnings Call Transcript
11:14am, Wednesday, 14'th Aug 2024
bluebird bio, Inc. (NASDAQ:BLUE ) Q2 2024 Results Conference Call August 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of Investor Relations Andrew Obenshain - CEO Tom Klima - C
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
07:00am, Wednesday, 14'th Aug 2024
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported second quarter results and business highlights for the quarter ended June
bluebird bio Announces Second Quarter 2024 Results Call Date
08:00am, Monday, 12'th Aug 2024
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14, at 8
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Blue Owl C
